Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates

被引:147
|
作者
Zhao, Robert Y. [1 ]
Wilhelm, Sharon D. [1 ]
Audette, Charlene [1 ]
Jones, Gregory [1 ]
Leece, Barbara A. [1 ]
Lazar, Alexandru C. [1 ]
Goldmacher, Victor S. [1 ]
Singh, Rajeeva [1 ]
Kovtun, Yelena [1 ]
Widdison, Wayne C. [1 ]
Lambert, John M. [1 ]
Chari, Ravi V. J. [1 ]
机构
[1] ImmunoGen Inc, Waltham, MA 02451 USA
关键词
CALICHEAMICIN CONJUGATE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; CANCER; CELLS; DOXORUBICIN; ACID; TRANSPORTERS; CHEMOTHERAPY; SPECIFICITY;
D O I
10.1021/jm2002958
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a negatively charged sulfonate group or a hydrophilic, noncharged PEG group in addition to an amine-reactive N-hydroxysuccinimide (NHS) ester and sulfhydryl reactive termini. These hydrophilic linkers enable conjugation of hydrophobic organic molecule drugs, such as a maytansinoid, at a higher drug/antibody ratio (DAR) than hydrophobic SPDB and SMCC linkers used earlier without triggering aggregation or loss of affinity of the resulting conjugate. Antibody maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly against multidrug resistant (MDR) cancer cell lines in vitro and tumor xenograft models in vivo.
引用
收藏
页码:3606 / 3623
页数:18
相关论文
共 50 条
  • [21] Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates
    Bryden, Francesca
    Martin, Camille
    Letast, Stephanie
    Lles, Eva
    Vieitez-Villemin, Inmaculada
    Rousseau, Anais
    Colas, Cyril
    Brachet-Botineau, Marie
    Allard-Vannier, Emilie
    Larbouret, Christel
    Viaud-Massuard, Marie-Claude
    Joubert, Nicolas
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2018, 16 (11) : 1882 - 1889
  • [22] Synthesis and Biological Evaluation of Antibody Drug Conjugates Based on an Antibody Expression System: Conamax
    Tawfiq, Zhala
    Caiazza, Nicky C.
    Kambourakis, Spiros
    Matsuda, Yutaka
    Griffin, Benjamin
    Lippmeier, J. Casey
    Mendelsohn, Brian A.
    ACS OMEGA, 2020, 5 (13): : 7193 - 7200
  • [23] Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers
    Salomon, Paulin L.
    Reid, Emily E.
    Archer, Katie E.
    Harris, Luke
    Maloney, Erin K.
    Wilhelm, Alan J.
    Miller, Michael L.
    Chari, Ravi V. J.
    Keating, Thomas A.
    Singh, Rajeeva
    MOLECULAR PHARMACEUTICS, 2019, 16 (12) : 4817 - 4825
  • [24] The design, synthesis, and evaluation of two universal doxorubicin-linkers: Preparation of conjugates that retain topoisomerase II activity
    Sun, CZ
    Aspland, SE
    Ballatore, C
    Castillo, R
    Smith, AB
    Castellino, AJ
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (01) : 104 - 107
  • [25] Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
    Lapusan, Simona
    Vidriales, Maria B.
    Thomas, Xavier
    de Botton, Stephane
    Vekhoff, Anne
    Tang, Ruoping
    Dumontet, Charles
    Morariu-Zamfir, Rodica
    Lambert, John M.
    Ozoux, Marie-Laure
    Poncelet, Philippe
    San Miguel, Jesus F.
    Legrand, Ollivier
    DeAngelo, Daniel J.
    Giles, Francis J.
    Marie, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1121 - 1131
  • [26] Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates
    Chuprakov, Stepan
    Ogunkoya, Ayodele O.
    Barfield, Robyn M.
    Bauzon, Maxine
    Hickle, Colin
    Kim, Yun Cheol
    Yeo, Dominick
    Zhang, Fangjiu
    Rabuka, David
    Drake, Penelope M.
    BIOCONJUGATE CHEMISTRY, 2021, 32 (04) : 746 - 754
  • [27] A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads
    Chia, C. S. Brian
    CHEMMEDCHEM, 2022, 17 (11)
  • [28] Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates
    Dal Corso, Alberto
    Cazzamalli, Samuele
    Gebleux, Remy
    Mattarella, Martin
    Neria, Dario
    BIOCONJUGATE CHEMISTRY, 2017, 28 (07) : 1826 - 1833
  • [29] Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates
    Kolodych, Sergii
    Michel, Chloe
    Delacroix, Sebastien
    Koniev, Oleksandr
    Ehkirch, Anthony
    Eberova, Jitka
    Cianferani, Sarah
    Renoux, Brigitte
    Krezel, Wojciech
    Poinot, Pauline
    Muller, Christian D.
    Papot, Sebastien
    Wagner, Alain
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 142 : 376 - 382
  • [30] Ferrocenylchalcone-uracil conjugates: synthesis and cytotoxic evaluation
    Singh, Amandeep
    Mehra, Vishu
    Sadeghiani, Neda
    Mozaffari, Saghar
    Parang, Keykavous
    Kumar, Vipan
    MEDICINAL CHEMISTRY RESEARCH, 2018, 27 (04) : 1260 - 1268